Tuspetinib
aptose biosciences
['leukemia', 'myeloid', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)']
$apto full poster presented at #ash22 #ash2022 a phase 1/2 open-label, multicenter, dose escalation and expansion study of the myeloid kinase
inhibitor hm43239 (tuspetinib) in patients with relapsed or refractory acute myeloid leukemia #aml 
Equity market consultant. Technical Analysis Trader with over 25 years of experience. Deep dive research, #Biotech Trading Analyst @ChimeraResearch